BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11384104)

  • 1. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
    Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
    Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
    Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
    Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
    Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
    Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
    Batra S; Reynolds CP; Maurer BJ
    Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
    Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
    Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide.
    Pellegrini R; Mariotti A; Tagliabue E; Bressan R; Bunone G; Coradini D; Della Valle G; Formelli F; Cleris L; Radice P
    Cell Growth Differ; 1995 Jul; 6(7):863-9. PubMed ID: 7547508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
    Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
    Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
    Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN
    Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression.
    Supino R; Crosti M; Clerici M; Warlters A; Cleris L; Zunino F; Formelli F
    Int J Cancer; 1996 Feb; 65(4):491-7. PubMed ID: 8621233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells.
    Prinetti A; Basso L; Appierto V; Villani MG; Valsecchi M; Loberto N; Prioni S; Chigorno V; Cavadini E; Formelli F; Sonnino S
    J Biol Chem; 2003 Feb; 278(8):5574-83. PubMed ID: 12486134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR.
    Holmes WF; Soprano DR; Soprano KJ
    J Cell Biochem; 2003 May; 89(2):262-78. PubMed ID: 12704790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells.
    Appierto V; Villani MG; Cavadini E; Lotan R; Vinson C; Formelli F
    Cell Death Differ; 2004 Mar; 11(3):270-9. PubMed ID: 14647238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
    Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
    Takahashi N; Sausville EA; Breitman TR
    Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide.
    Morales MC; Pérez-Yarza G; Nieto-Rementeria N; Boyano MD; Jangi M; Atencia R; Asumendi A
    Anticancer Res; 2005; 25(3B):1945-51. PubMed ID: 16158929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.